Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: Prognosis of subtypes defined in the WHO-EORTC classification

British Journal of Dermatology

Volumn 167, Issue 5, 2012, Pages 1118-1123

  Bessell, E M ^a   Humber, C E ^a   O'Connor, S ^b   English, J S E ^c   Perkins, W ^c   Dickinson, P D ^a   Patel, A N ^c  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; B CELL LYMPHOMA; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA SPECIFIC SURVIVAL; MAJOR CLINICAL STUDY; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIMARY CUTANEOUS B CELL LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RARE DISEASE; REVIEW; SKIN LYMPHOMA; TREATMENT RESPONSE; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

EID: 84868211143     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11122.x     Document Type: Review

References (24)

1. Groves FD, Linet MS, Travis LB, Devesa SS,. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92: 1240-51.
2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
3. Baldassano MF, Bailey EM, Ferry JA, et al. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features. Am J Surg Pathol 1999; 23: 88-96.
4. Bergman R,. Pseudolymphoma and cutaneous lymphoma: facts and controversies. Clin Dermatol 2010; 28: 568-74.
5. Child FJ, Russell-Jones R, Woolford AJ, et al. Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma. Br J Dermatol 2001; 144: 735-44.
6. Russell-Jones R,. Primary cutaneous B-cell lymphoma: how useful is the new European Organization for Research and Treatment of Cancer (EORTC) classification? Br J Dermatol 1998; 139: 945-9.
7. Rijlaarsdam JU, Toonstra J, Meijer OW, et al. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol 1996; 14: 549-55.
8. Bekkenk MW, Vermeer MH, Geerts ML, et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol 1999; 17: 2471-8.
9. Eich HT, Eich D, Micke O, et al. Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma. Int J Radiat Oncol Biol Phys 2003; 55: 899-906.
10. Smith BD, Glusac EJ, McNiff JM, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 2004; 22: 634-9.
11. Senff NJ, Hoefnagel JJ, Neelis KJ, et al.; Dutch Cutaneous Lymphoma Group. Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 2007; 143: 1520-6.
12. Heinzerling LM, Urbanek M, Funk JO, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-44.
13. El-Helw L, Goodwin S, Slater D, Hancock BW,. Primary B-cell lymphoma of the skin: the Sheffield Lymphoma Group Experience (1984-2003). Int J Oncol 2004; 25: 1453-8.
14. Sah A, Barrans SL, Parapia LA, et al. Cutaneous B-cell lymphoma: pathological spectrum and clinical outcome in 51 consecutive patients. Am J Hematol 2004; 75: 195-9.
15. Hallermann C, Niermann C, Fischer RJ, Schulze HJ,. Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study. Acta Derm Venereol 2011; 91: 521-5.
16. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
17. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-86.
18. Bessell EM, Burton A, Haynes AP, et al.; Central Lymphoma Group UK. A randomised multicentre trial of modified CHOP vs. MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14: 258-67.
19. Bradford PT, Devesa SS, Anderson WF, Toro JR,. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-73.
20. Smith BD, Smith GL, Cooper DL, Wilson LD,. The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. J Clin Oncol 2005; 23: 3390-5.
21. Mian M, Marcheselli L, Luminari S, et al. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). Ann Hematol 2011; 90: 401-8.
22. Senff NJ, Noordijk EM, Kim YH, et al.; European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112: 1600-9.
23. Neelis KJ, Schimmel EC, Vermeer MH, et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys 2009; 74: 154-8.
24. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B cell lymphoma, leg type. Clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007; 143: 1144-50.